Skip to Main Content

HIV-1/2 Antibody Plus Antigen-Fourth Generation

Principle

This assay is an in vitro Enzyme-Linked Immunosorbent Assay (ELISA) designed for the simultaneous qualitative detection of antibodies to human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2), as well as HIV-1 p24 antigen, in human serum. A reactive result indicates the presence of HIV-1 or HIV-2 antibodies and/or p24 antigen.

HIV-1, the first identified causative agent of AIDS, is transmitted through sexual contact, exposure to infected blood or blood products, or from an infected mother to her fetus or child. The prevalence of HIV-1 antibodies is high among individuals with AIDS, AIDS-related complex (ARC), and those at increased risk. Recombinant DNA–derived antigens corresponding to HIV-1 core and envelope proteins and the HIV-2 envelope protein allow for the detection of anti–HIV-1 and/or anti–HIV-2 antibodies.

HIV-2 is similar to HIV-1 in morphology, CD4 cell tropism, interaction with the CD4 receptor, genomic structure, cytopathic effects, transmission routes, and its ability to cause AIDS.

Specimens that are initially reactive must be retested in duplicate using the original serum sample. Repeat reactivity in either or both duplicate tests (repeatable reactive) is highly predictive of HIV-1 and/or HIV-2 antibodies, particularly in individuals at increased risk for infection. However, due to the possibility of nonspecific reactivity—especially in populations with low disease prevalence (e.g., blood donors)—confirmatory testing using HIV-1 and HIV-2 Western blot or another approved supplemental assay is required to verify the presence of HIV antibodies.

Specimen Requirements

Specimen

Serum

Collection

Collect 2 mL of serum in a red-top tube (no additives) or a serum separator tube (gel barrier).

Processing

Separate serum from the clot as soon as possible to avoid hemolysis.

Storage and Transport

  • 2–8 °C: up to 1 week
  • −20 °C or lower: for longer storage
  • Avoid repeated freeze–thaw cycles

Method

Enzyme-Linked Immunosorbent Assay (ELISA).

Normal Range

Non-reactive

Turnaround Time

One Week

References

  • Feorino, P.M., Jaffe, H.W., Palmer, E. et al. Transfusion-associated acquired immunodeficiency syndrome: evidence for persistent infection in blood donors. New Engl J Med 312 (20):1293-6; 1985.
  • Sheehan, C. Clinical Immunology: Principl

Back to Reproductive Immunology